A detailed history of Signaturefd, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 561 shares of SUPN stock, worth $19,158. This represents 0.0% of its overall portfolio holdings.

Number of Shares
561
Previous 561 -0.0%
Holding current value
$19,158
Previous $15,000 13.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$25.99 - $33.85 $2,495 - $3,249
-96 Reduced 14.61%
561 $15,000
Q1 2024

May 03, 2024

SELL
$27.11 - $35.17 $189 - $246
-7 Reduced 1.05%
657 $22,000
Q4 2023

Jan 31, 2024

BUY
$22.72 - $29.68 $5,021 - $6,559
221 Added 49.89%
664 $19,000
Q3 2023

Nov 03, 2023

BUY
$27.57 - $32.91 $606 - $724
22 Added 5.23%
443 $12,000
Q2 2023

Aug 01, 2023

SELL
$29.91 - $38.73 $957 - $1,239
-32 Reduced 7.06%
421 $12,000
Q1 2023

Apr 28, 2023

SELL
$34.93 - $42.03 $69 - $84
-2 Reduced 0.44%
453 $16,000
Q3 2022

Nov 08, 2022

BUY
$28.79 - $35.41 $4,606 - $5,665
160 Added 54.24%
455 $15,000
Q2 2022

Aug 10, 2022

BUY
$25.33 - $34.25 $101 - $137
4 Added 1.37%
295 $9,000
Q4 2020

Feb 11, 2021

SELL
$17.7 - $25.81 $601 - $877
-34 Reduced 10.46%
291 $7,000
Q3 2020

Nov 03, 2020

BUY
$20.2 - $25.05 $3,999 - $4,959
198 Added 155.91%
325 $7,000
Q2 2020

Jul 30, 2020

BUY
$17.09 - $24.89 $2,170 - $3,161
127 New
127 $3,000
Q1 2020

Apr 23, 2020

SELL
$14.45 - $24.69 $274 - $469
-19 Closed
0 $0
Q1 2018

May 08, 2018

BUY
$37.15 - $46.9 $705 - $891
19 New
19 $1,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.83B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.